Evidence map›Paper›PMID 24628910›Full record

ReviewJournal of orthopaedic surgery and research2014

Bone regenerative medicine: classic options, novel strategies, and future directions.

Ahmad Oryan, Soodeh Alidadi, Ali Moshiri, Nicola Maffulli

Abstract readReview
In one paragraph

Review in Journal of orthopaedic surgery and research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 453 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
453citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

453 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Speed and quality of interbody fusion in porous bioceramic AlJournal of orthopaedic surgery and research · 2023
    Trial
  6. iScience · 2026
    Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Application and prospects of nanomaterials in osteoporosis treatment.International journal of pharmaceutics: X · 2026
    Review
  19. Article
  20. Review

393 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ahmad Oryan
Soodeh Alidadi
Ali MoshiriDivision of Surgery and Radiology, Department of Clinical Sciences, School of Veterinary Medicine, Shiraz University, Shiraz 71345, Iran. dr.ali.moshiri@gmail.com.
Nicola Maffulli

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review analyzes the literature of bone grafts and introduces tissue engineering as a strategy in this field of orthopedic surgery. We evaluated articles concerning bone grafts; analyzed characteristics, advantages, and limitations of the grafts; and provided explanations about bone-tissue engineering technologies. Many bone grafting materials are available to enhance bone healing and regeneration, from bone autografts to graft substitutes; they can be used alone or in combination. Autografts are the gold standard for this purpose, since they provide osteogenic cells, osteoinductive growth factors, and an osteoconductive scaffold, all essential for new bone growth. Autografts carry the limitations of morbidity at the harvesting site and limited availability. Allografts and xenografts carry the risk of disease transmission and rejection. Tissue engineering is a new and developing option that had been introduced to reduce limitations of bone grafts and improve the healing processes of the bone fractures and defects. The combined use of scaffolds, healing promoting factors, together with gene therapy, and, more recently, three-dimensional printing of tissue-engineered constructs may open new insights in the near future.

Indexed as

Bone RegenerationBone SubstitutesAnimalsBone DiseasesBone TransplantationHumansOsteogenesisRegenerative MedicineTissue EngineeringTreatment OutcomeBone Substitutes

Identifiers

PMID24628910
PMCPMC3995444

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.